USPTO Examiner PEEBLES KATHERINE - Art Unit 1617

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18623761COMPACTABLE ORAL FORMULATIONS OF IBUTAMORENApril 2024June 2025Allow1421YesNo
18416354THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USEJanuary 2024December 2024Allow1110NoNo
18542163PHARMACEUTICAL LIQUID COMPOSITIONS OF MELOXICAMDecember 2023February 2025Allow1420YesYes
18238303PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND METHODS FOR MAKING AND USING SAMEAugust 2023December 2024Abandon1511NoNo
18323040PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMMay 2023April 2024Abandon1010NoNo
18317654Compositions Containing Dofetilide and Mexiletine and Uses ThereofMay 2023September 2024Allow1621YesNo
18132545LIQUID PHARMACEUTICAL FORMULATIONApril 2023July 2024Allow1610YesNo
18190060CO-CRYSTAL COMPOUNDS COMPRISING LITHIUM IONS AND ISONICOTINAMIDEMarch 2023November 2024Allow2011YesNo
18119806IN SITU TREATMENT OF SEED IN FURROWMarch 2023September 2024Abandon1801NoNo
18176204ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAMEFebruary 2023October 2024Abandon2030YesNo
18110581COMPOSITION COMPRISING CINNAMALDEHYDE AND ZINC TO IMPROVE SWALLOWINGFebruary 2023May 2024Allow1410YesNo
18110202FORMULATIONS OF VASOPRESSINFebruary 2023July 2024Abandon1710NoNo
18106659NANOPARTICLE COMPOSITIONS COMPRISING CANNABINOIDSFebruary 2023May 2024Abandon1510NoNo
18057941COMPACTABLE ORAL FORMULATIONS OF IBUTAMORENNovember 2022March 2024Allow2630YesNo
17999321COMPOSITIONS COMPRISING ORGANO-SILANOL COMPOUNDS, AND APPLICATIONSNovember 2022June 2024Allow1921YesNo
17926267A TOPICAL ANTIMICROBIAL COMPOSITIONNovember 2022July 2024Allow2020YesNo
17970192THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USEOctober 2022January 2025Abandon2710NoNo
17967783LINEZOLID FORMULATIONSOctober 2022April 2025Abandon3021YesYes
17966148Composition For Surface ModificationOctober 2022March 2025Allow2921YesNo
17941384METHOD FOR DELIVERING INSULINSeptember 2022January 2025Allow2821YesNo
17930713LONG-ACTING INJECTION DOSAGE FORM OF BETA 3 ADRENORECEPTOR AGONISTSSeptember 2022December 2023Abandon1510NoNo
17929461METHODS USING PHOSPHATIDYLSERINE POWDERSeptember 2022February 2025Abandon2930NoNo
17865734SOLID ORAL DOSAGE FORM OF IRINOTECAN FOR THE TREATMENT OF CANCERJuly 2022February 2023Allow700YesNo
17850854COMBINATION PRODUCTS OF TOBRAMYCIN COMPOUNDS AND DEXAMETHASONE COMPOUNDSJune 2022November 2024Abandon2940NoNo
17834809POLYMORPHIC FORMS OF SODIUM BENZOATE AND USES THEREOFJune 2022February 2024Abandon2111NoNo
17746647Antipsychotic Injectable Depot CompositionMay 2022April 2023Allow1110YesNo
17744713ENDOPHYTIC FALCIPHORA ORYZAE FO-R20 AND ITS APPLICATIONMay 2022April 2025Allow3521NoNo
17725772PHARMACEUTICAL LIQUID COMPOSITIONS OF MELOXICAMApril 2022June 2024Abandon2641YesNo
17721742METHODS FOR PREVENTION AND TREATMENT OF FIBROMYALGIA BY CONTACT VASODILATORSApril 2022September 2023Abandon1711NoNo
17719686Dosing Regimens Associated With Extended Release Paliperidone Injectable FormulationsApril 2022May 2025Allow3720NoNo
17698537PHARMACEUTICAL COMPOSITIONS OF BORTEZOMIBMarch 2022April 2024Abandon2550NoNo
17675780PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND METHODS FOR MAKING AND USING SAMEFebruary 2022May 2023Allow1521YesNo
17672927Antipsychotic Injectable Depot CompositionFebruary 2022April 2023Allow1410YesNo
17669595COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONFebruary 2022October 2023Abandon2021YesNo
17584553FORMULATIONS INCLUDING DIHYDROHONOKIOLJanuary 2022September 2023Abandon2021NoNo
17630403ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAMEJanuary 2022March 2025Allow3711NoNo
17577170Antipsychotic Injectable Depot CompositionJanuary 2022May 2023Allow1610YesNo
17423210Parenteral Pharmaceutical Composition Comprising Azacitidine or Decitabine in DMSODecember 2021November 2023Abandon2840NoNo
17527928MEDICAMENT CONTAINING MODIFIED STARCH FOR THE TREATMENT OF ANASTOMOSESNovember 2021July 2023Abandon2001NoNo
17594373BACTERICIDAL AGENT FOR AGRICULTURAL OR HORTICULTURAL USE, PLANT DISEASE CONTROL METHOD, AND PRODUCT FOR PLANT DISEASE CONTROL USEOctober 2021August 2024Allow3451YesNo
17498514Risperidone or Paliperidone Implant FormulationOctober 2021March 2025Allow4110NoNo
17470471THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USESeptember 2021August 2022Allow1111YesNo
17465062HAND SANITIZERS WITH IMPROVED AESTHETICS AND SKIN-CONDITIONING TO ENCOURAGE COMPLIANCE WITH HAND HYGIENE GUIDELINESSeptember 2021February 2024Allow2930YesNo
17412189Natural Concentrated Composition for Killing and Repelling PestsAugust 2021August 2024Abandon3610NoNo
17405462Foaming Topical Antimicrobial Cleaning CompositionsAugust 2021December 2024Abandon4040YesNo
17424321METHODS FOR TREATING SCHIZOPHRENIAJuly 2021March 2025Abandon4430NoNo
17378458PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND METHODS FOR MAKING AND USING SAMEJuly 2021October 2022Allow1521YesNo
17423378Drug Delivery SystemJuly 2021June 2025Abandon4731YesNo
17368367PHARMACEUTICAL LIQUID COMPOSITIONS OF MELOXICAMJuly 2021February 2024Abandon3211NoNo
17364469LONG-ACTING INJECTION DOSAGE FORM OF BETA 3 ADRENORECEPTOR AGONISTSJune 2021December 2022Allow1820YesNo
17304578Cleansing CompositionsJune 2021November 2023Allow2911YesNo
17340594PROCESS FOR DEPIGMENTING KERATIN MATERIALS USING THIOPYRIDINONE COMPOUNDSJune 2021June 2024Abandon3711YesNo
17327703COMBINATION PRODUCTS OF TOBRAMYCIN COMPOUNDS AND DEXAMETHASONE COMPOUNDSMay 2021March 2022Allow1011YesNo
17318586AZELAIC ACID ESTERS IN THE TREATMENT OF INSULIN RESISTANCEMay 2021March 2025Allow4640YesYes
17314330Dosing Regimens Associated With Extended Release Paliperidone Injectable FormulationsMay 2021October 2021Allow610YesNo
17289768COMPOSITIONS COMPRISING PYRIDINE CARBOXYLATE HERBICIDES AND PLANT GROWTH REGULATORSApril 2021September 2024Abandon4101NoNo
17231761FORMULATION BASED ON VITAMIN E OR AN ESTER THEREOF FOR TREATING BACTERIAL AND FUNGAL BIOFILMSApril 2021June 2023Abandon2610NoNo
17227940ANTIBACTERIAL NANOFIBERApril 2021October 2023Allow3020YesNo
17204183PACLITAXEL-HYALURONIC ACID CONJUGATE IN THE TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCERMarch 2021January 2024Abandon3420NoNo
17273828SUSTAINED-RELEASE INJECTABLE ANTIBIOTICAL FORMULATIONMarch 2021August 2024Abandon4120NoNo
17182425COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING RESPIRATORY VIRAL INFECTIONS USING GREEN TREE EXTRACTFebruary 2021February 2024Abandon3611NoNo
17267917COMPOSITION OF MICRONUTRIENTS AND ORGANIC COMPOUNDS FOR TREATING, COATING AND ENCRUSTING SEEDSFebruary 2021October 2024Abandon4410NoNo
17172771INJECTABLE COMPOSITION WITH AROMATASE INHIBITORFebruary 2021November 2023Allow3320YesNo
17104337Methods for the Preparation of Injectable Depot CompositionsNovember 2020April 2023Allow2910YesNo
17074619Radiation-Sterilized Biodegradable Drug Delivery CompositionsOctober 2020June 2023Abandon3201NoNo
17067187REDUCED VOLUME FORMULATIONS INCLUDING AMINO ACID ENTITIESOctober 2020December 2023Abandon3811NoNo
17045325PHARMACEUTICAL COMPOSITIONS WITH REDUCED TERT-BUTANOL LEVELSOctober 2020April 2023Abandon3111NoNo
16948832NOVEL ARTIFICIAL TEARS CONTAINING RECOMBINANT HUMAN LYSOZYME AND RECOMBINANT HUMAN EGFOctober 2020February 2024Abandon4120NoNo
17042795LIQUID PHARMACEUTICAL FORMULATIONSeptember 2020December 2022Allow2621YesNo
17032934ABUSE-RESISTANT PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OPIOID DEPENDENCESeptember 2020March 2021Allow500YesNo
17032882ABUSE-RESISTANT PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OPIOID DEPENDENCESeptember 2020September 2021Allow1110YesNo
17033019ABUSE-RESISTANT PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OPIOID DEPENDENCESeptember 2020March 2021Allow600YesNo
17032585Foaming Topical Antimicrobial Cleaning CompositionsSeptember 2020July 2024Abandon4640YesNo
17021739PREPARATION OF THERAPEUTIC FOAMSeptember 2020November 2021Allow1400YesNo
16980204IMMUNOREGULATORY ROLE OF 3-OH-KYNURENAMINE AND USES THEREOFSeptember 2020March 2023Allow3001YesNo
17009702ABUSE-RESISTANT PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OPIOID DEPENDENCESeptember 2020January 2021Allow500YesNo
16993017AQUEOUS FORMULATION FOR INSOLUBLE DRUGSAugust 2020October 2022Allow2630YesNo
16967993EPIGENETIC HISTONE REGULATION MEDIATED BY CXorf67August 2020January 2025Abandon5311YesNo
16967411LIQUID COMPOSITIONS OF APREPITANTAugust 2020August 2024Abandon4931YesNo
16945985METHOD OF PREPARING CONDITIONER FOR PROTECTED AGRICULTURE ACIDIC SOIL WITH DISTILLERS' GRAINS AND USEAugust 2020February 2025Abandon5431NoNo
16944639POWDER COATING COMPOSITIONS FOR COATING PHARMACEUTICAL PELLETSJuly 2020March 2023Abandon3220YesNo
16945053PENETRATING PAIN RELIEF CREAMJuly 2020May 2022Allow2101YesNo
16934807PROCESS FOR THE PREPARATION OF STERILE OPHTHALMIC AQUEOUS FLUTICASONE PROPIONATE FORM A NANOCRYSTALS SUSPENSIONSJuly 2020March 2022Allow1921YesNo
16924529Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses ThereofJuly 2020September 2023Abandon3820NoYes
16920556CATIONIC LIPIDS AND TRANSFECTION METHODSJuly 2020March 2025Allow5631YesNo
16959979PACLITAXEL-HYALURONIC ACID CONJUGATE IN THE TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCERJuly 2020July 2021Abandon1310NoNo
16959657ORAL LIQUID PHARMACEUTICAL COMPOSITIONS OF AMINOSALICYLATESJuly 2020May 2025Abandon5931NoNo
16909197Composition For Surface ModificationJune 2020August 2022Allow2621YesNo
16956631NOVEL FORMULATIONS OF VASOPRESSINJune 2020March 2023Abandon3330NoNo
16892550Cannabinoids and Pearl Powder TopicalJune 2020March 2023Abandon3420NoNo
16767706LIQUID FORMULATIONS OF RILUZOLE FOR ORAL AND INTRAVENOUS USEMay 2020July 2023Abandon3721NoNo
16881277RISPERIDONE-CONTAINING MICROCAPSULE, METHOD FOR PREPARING SAME AND RELEASE CONTROL METHODMay 2020April 2022Abandon2310NoNo
16764468LINEZOLID FORMULATIONSMay 2020July 2022Allow2621YesNo
16868307SOLID DISPERSION OF RIFAXIMINMay 2020May 2024Abandon4820NoNo
16868013MODIFIED CYCLIC DINUCLEOSIDE COMPOUNDS AS STING MODULATORSMay 2020May 2023Allow3721YesNo
16760736SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITIONApril 2020April 2022Abandon2301NoNo
16760595EXTERNAL PREPARATION FOR TREATING TRICHOPHYTOSIS UNGUIUMApril 2020May 2023Allow3711NoNo
16860373METHOD OF PROVIDING HIGH STABILITY NON-IONIC N-VINYL BUTYROLACTAM IODINEApril 2020October 2024Abandon5341YesNo
16859628TOPICAL FORMULATION CONTAINING PAPAVERINE AND SILDENAFIL AND USES THEREOFApril 2020May 2022Abandon2510NoNo
16758272PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREOFApril 2020September 2023Allow4121YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PEEBLES, KATHERINE.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
15
Examiner Affirmed
12
(80.0%)
Examiner Reversed
3
(20.0%)
Reversal Percentile
29.8%
Lower than average

What This Means

With a 20.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
57
Allowed After Appeal Filing
9
(15.8%)
Not Allowed After Appeal Filing
48
(84.2%)
Filing Benefit Percentile
16.2%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 15.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner PEEBLES, KATHERINE - Prosecution Strategy Guide

Executive Summary

Examiner PEEBLES, KATHERINE works in Art Unit 1617 and has examined 499 patent applications in our dataset. With an allowance rate of 38.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.

Allowance Patterns

Examiner PEEBLES, KATHERINE's allowance rate of 38.7% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by PEEBLES, KATHERINE receive 2.85 office actions before reaching final disposition. This places the examiner in the 93% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by PEEBLES, KATHERINE is 31 months. This places the examiner in the 34% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +52.9% benefit to allowance rate for applications examined by PEEBLES, KATHERINE. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 10.0% of applications are subsequently allowed. This success rate is in the 2% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 18.1% of cases where such amendments are filed. This entry rate is in the 14% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 10.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 22% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 53.1% of appeals filed. This is in the 19% percentile among all examiners. Of these withdrawals, 41.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 51.6% are granted (fully or in part). This grant rate is in the 64% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.4% of allowed cases (in the 57% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.1% of allowed cases (in the 66% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.